Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Veiga

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
JAMA|August 10, 2021
Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical TrialFernando G Zampieri, Flávia R Machado, Rodrigo S Biondi, et al.
JAMA|September 21, 2021
Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical TrialFernando G Zampieri, Flávia R Machado, Rodrigo S Biondi, et al.
Lancet (London, England)|September 8, 2020
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trialRemo H M Furtado, Otavio Berwanger, Henrique A Fonseca, et al.
JAMA|September 3, 2020
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical TrialBruno M Tomazini, Israel S Maia, Alexandre B Cavalcanti, et al.
BMJ (Clinical Research Ed.)|January 21, 2021
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trialViviane C Veiga, João A G G Prats, Danielle L C Farias, et al.
Lancet Regional Health. Americas|February 24, 2026
Daily Chlorhexidine Bathing for the Prevention of Nosocomial Infections in Critically Ill Patients (CLEAN-IT): a multicentre, cluster-randomised, crossover trialBruno M Tomazini, Bruno A M P Besen, Ana C Gales, et al.
The New England Journal of Medicine|July 25, 2020
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19Alexandre B Cavalcanti, Fernando G Zampieri, Regis G Rosa, et al.
Lancet Regional Health. Americas|April 5, 2022
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trialÁlvaro Avezum, Gustavo B F Oliveira, Haliton Oliveira, et al.
Lancet Regional Health. Americas|March 13, 2023
Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn trialIsrael S Maia, Aline Marcadenti, Viviane C Veiga, et al.
Journal of Thrombosis and Thrombolysis|May 18, 2024
Predictors of bleeding and thrombotic events among patients admitted to the hospital with COVID-19 and elevated D-dimer: insights from the ACTION randomized clinical trialPedro Gabriel Melo de Barros E Silva, Remo H M Furtado, Mariana Silveira de Alcântara Chaud, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
JAMA|August 10, 2021
Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical TrialFernando G Zampieri, Flávia R Machado, Rodrigo S Biondi, et al.
JAMA|September 21, 2021
Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical TrialFernando G Zampieri, Flávia R Machado, Rodrigo S Biondi, et al.
Lancet (London, England)|September 8, 2020
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trialRemo H M Furtado, Otavio Berwanger, Henrique A Fonseca, et al.
JAMA|September 3, 2020
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical TrialBruno M Tomazini, Israel S Maia, Alexandre B Cavalcanti, et al.
BMJ (Clinical Research Ed.)|January 21, 2021
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trialViviane C Veiga, João A G G Prats, Danielle L C Farias, et al.
Lancet Regional Health. Americas|February 24, 2026
Daily Chlorhexidine Bathing for the Prevention of Nosocomial Infections in Critically Ill Patients (CLEAN-IT): a multicentre, cluster-randomised, crossover trialBruno M Tomazini, Bruno A M P Besen, Ana C Gales, et al.
The New England Journal of Medicine|July 25, 2020
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19Alexandre B Cavalcanti, Fernando G Zampieri, Regis G Rosa, et al.
Lancet Regional Health. Americas|April 5, 2022
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trialÁlvaro Avezum, Gustavo B F Oliveira, Haliton Oliveira, et al.
Lancet Regional Health. Americas|March 13, 2023
Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn trialIsrael S Maia, Aline Marcadenti, Viviane C Veiga, et al.
Journal of Thrombosis and Thrombolysis|May 18, 2024
Predictors of bleeding and thrombotic events among patients admitted to the hospital with COVID-19 and elevated D-dimer: insights from the ACTION randomized clinical trialPedro Gabriel Melo de Barros E Silva, Remo H M Furtado, Mariana Silveira de Alcântara Chaud, et al.
Pageof 22